SYDNEY — Telix Pharmaceuticals Ltd (ASX: TLX) led the S&P/ASX 200 gainers Friday with a 3.23 percent surge to $14.08 after the U.S. Food and Drug Administration accepted its resubmitted New Drug Application for TLX101-Px (Pixclara), an investigational PET imaging agent for brain cancer (glioma). The move highlighted selective strength in healthcare amid a cautious broader market where the benchmark index eased around 0.55 percent.

ASX 200 Top Gainers: Telix Pharma Jumps 3.23% on FDA
ASX 200 Top Gainers: Telix Pharma Jumps 3.23% on FDA Nod as Healthcare Leads Mixed Session Amid Oil Rebound

Bendigo and Adelaide Bank (ASX: BEN) ranked second among notable risers, climbing about 2.03 percent to $11.57 on continued momentum from its recent third-quarter trading update and strategic partnerships. Sigma Healthcare (ASX: SIG) advanced 1.67 percent to $2.75, Bluescope Steel (ASX: BSL) gained 1.55 percent to $28.45, and Magellan Financial Group (ASX: MFG) rose 1.50 percent to $9.48, rounding out the session's standout performers in a risk-off environment.

The S&P/ASX 200 closed near 8,954 after trading in a range and shedding roughly 19 points, or 0.21 percent at one point, with the All Ordinaries and Small Ordinaries also posting modest declines. Volume was solid as investors digested a fragile U.S.-Iran ceasefire, sticky oil prices rebounding toward $98-99 per barrel, and sector rotation away from recent tech and resources strength.

Telix's gain capped a strong month for the radiopharmaceutical company, with shares up more than 31 percent since mid-March. The FDA acceptance, announced early Friday, assigns a PDUFA goal date of Sept. 11, 2026, for the imaging agent designed to characterize recurrent or progressive glioma in adult and pediatric patients. TLX101-Px has Orphan Drug and Fast Track designations, underscoring its potential in a high-unmet-need area.

Telix executives noted the acceptance validates the additional clinical data and analysis provided in the resubmission, addressing a prior Complete Response Letter. The company's precision medicine portfolio, including its commercial Illuccix product, continues to deliver revenue growth, with first-quarter 2026 figures showing solid expansion. Analysts viewed the regulatory progress as de-risking a key pipeline asset, though Telix's full-year guidance excludes any near-term revenue from Pixclara.

Bendigo and Adelaide Bank's resilience extended gains from Thursday's sharp 8.41 percent jump to $11.34 on its Q3 cash earnings update and productivity program announcements. The regional lender reported unaudited cash earnings of $137.9 million for the quarter, up 7.6 percent, with a stable net interest margin of 1.98 percent benefiting from deposit pricing. New strategic partnerships with Infosys and Genpact aim to simplify operations and enhance efficiency as part of its 2030 strategy.

The bank's focus on customer deposits and disciplined lending in a higher-rate environment has resonated with investors seeking defensive financial exposure. Bendigo maintained a robust capital position and dividend outlook, appealing to income-focused superannuation funds.

Sigma Healthcare, a leading pharmaceutical wholesaler and retailer, benefited from steady defensive demand in the staples sector, which outperformed on the day. The company's diversified operations across pharmacy and healthcare services provided stability amid volatility in resources and technology.

Bluescope Steel gained on expectations of sustained demand for steel products, even as broader resources eased slightly. The company's exposure to construction and manufacturing supported its relative strength.

Magellan Financial Group, an active fund manager, saw buying interest as investors rotated toward financial services names with potential for outperformance if rates remain elevated longer than anticipated.

The session's modest top gains — mostly in the 1-3 percent range for ASX 200 names — contrasted with sharper moves in smaller caps, where lithium and resources explorers posted double-digit percentage jumps on speculation. The benchmark's overall tone reflected profit-taking after a strong relief rally earlier in the week driven by initial ceasefire optimism.

Oil prices rebounded as concerns persisted over the Strait of Hormuz, where shipping traffic remained heavily constrained. Energy stocks showed mixed results, with some support from higher crude but limited broad participation. Gold names faced headwinds after recent safe-haven buying, contributing to weakness in resources.

Utilities and staples sectors provided defensive support, aligning with the day's top performers in healthcare and financials. Technology stocks pulled back further, extending recent losses amid global AI and tech sector caution.

The fragile Middle East ceasefire continued to dominate macro narratives. While the truce initially sparked a broad rally across risk assets, unresolved issues — including secondary conflicts and supply disruptions — kept volatility elevated. Economists noted potential inflationary risks from sustained higher energy costs, which could influence the Reserve Bank of Australia's policy path.

The RBA has held rates steady recently, but persistent oil-driven pressures could limit near-term easing. This environment favors banks with strong deposit franchises and healthcare names with non-cyclical demand.

Corporate news flow remained light on Friday, with focus shifting to upcoming economic data and earnings. Bendigo's recent update and Telix's FDA milestone provided the clearest catalysts among larger-cap movers.

Analysts maintained broadly positive longer-term views on the highlighted names. Telix's pipeline progress positions it as a leader in targeted radiopharmaceuticals, a growing field with applications beyond oncology. Bendigo's productivity initiatives and regional focus could drive further efficiency gains and market share.

For the ASX 200 overall, Friday's session represented consolidation after recent volatility tied to geopolitics and commodity swings. The index remains below its 2026 highs but has recovered some ground on hopes for de-escalation abroad.

Investors will monitor any further diplomatic developments in the Middle East over the weekend, along with oil inventory data and global inflation signals. Domestically, attention turns to labor market and inflation figures that will shape expectations for monetary policy.

The selective nature of Friday's gains — led by Telix on regulatory news and supported by banks and defensives — underscores how company-specific catalysts can shine through in uncertain markets. While the benchmark eased, these outperformers illustrated pockets of resilience in healthcare innovation and financial stability.

As the trading week concluded, the ASX 200's top five gainers captured themes of regulatory advancement, operational efficiency and defensive appeal. Telix's FDA acceptance in particular offered a bright spot, reminding investors of Australia's growing role in global biotech and precision medicine.

Whether these moves signal broader rotation or remain isolated will depend on ceasefire durability and central bank signals. For now, they provided notable highlights in an otherwise subdued close for Australian equities.